Enliven Therapeutics, Inc. (ELVN) Operating income 2019–2025
Enliven Therapeutics, Inc. (ELVN) annual operating income history from SEC filings — each fiscal year as reported.
-$119.7MFY2025 · since FY2019: -$24.1M → -$119.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$119.7M | -14.4% |
| FY2024 | -$104.6M | -25.2% |
| FY2023 | -$83.5M | -115.3% |
| FY2022 | -$38.8M | -56.7% |
| FY2021 | -$24.8M | +40.6% |
| FY2020 | -$41.7M | -72.9% |
| FY2019 | -$24.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice